Xianju Pharmaceutical announced that its Ethinylestradiol Cyproterone Acetate Tablets have passed the generic drug quality and efficacy consistency evaluation, receiving the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration. Each tablet contains 2 mg of cyproterone acetate and 0.035 mg of ethinylestradiol, indicated for the treatment of moderate to severe acne and/or hirsutism in women of reproductive age, especially those with polycystic ovary syndrome. In the first quarter of 2026, Xianju Pharmaceutical achieved revenue of 918 million yuan and a net profit attributable to the parent company of 93.89 million yuan.
Zhejiang Xianju Pharmaceutical Co LtdPassed consistency evaluation, receiving approval notice from NMPA.